P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Background Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalizations for heart failure in patients with or without diabetes. More evidence is needed regarding their effects across the broad spectrum of heart failure, including those with reduced ejection fraction (HFrEF). Methods We randomly assigned, in double-blind fashion, 3730 patients with class II-IV heart failure and left ventricular ejection fraction ≤40% to receive...